EUMETSAT Takes Control of Europe's First Geostationary Sounder Satellite
After more than two weeks of complex manoeuvring, precise positioning and meticulous checks, EUMETSAT assumed control of the Meteosat Third Generation Sounder 1 (MTG-S1) spacecraft on 18 July 2025, the latest addition to its fleet of geostationary meteorological satellites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250720937880/en/
MTG-S1 in orbit
Following MTG-S1's successful launch on 1 July 2025, the satellite, which carries the Infrared Sounder (IRS) and the European Union's Copernicus Sentinel-4 mission, has completed its launch and early operations phase (LEOP) and is now in orbit around 36,000km above the Equator at 3.4°W longitude.
MTG-S1 will now begin months of intensive testing by experts at EUMETSAT with partners from the European Space Agency (ESA) and in industry to prepare for the delivery of vital data and products to specialists across EUMETSAT member states and beyond. Once fully commissioned, the satellite will deliver entirely new streams of atmospheric sounding data, enabling national meteorological services to deliver earlier and more accurate warnings that will save lives and protect property and infrastructure.
'The successful completion of the LEOP confirms that the MTG-S1 satellite platform is functioning as expected and ready for the next stage,' said Julia Hunter-Anderson, EUMETSAT's Meteosat Third Generation LEOP Manager. 'Taking control of the satellite in a healthy condition marks a major milestone for EUMETSAT and our partners. This achievement is the culmination of the immense dedication and hard work of hundreds of people over many years.
'For EUMETSAT, it is also the beginning of another journey: together with ESA and industry to commission the satellite and prepare its remarkable instruments to deliver critical near-real-time sounding data and products. These observations will inform decision makers, help protect societies, improve lives and livelihoods, and enhance how we monitor the climate and forecast weather across our member states and beyond.'
For further updates on MTG-S1, visit EUMETSAT's launch hub, which features news, interviews, and insights into the satellite's journey.
Find all relevant information, biographies of speakers, videos and testimonials on our dedicated press page.
About EUMETSAT
EUMETSAT, Europe's meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
For more information: EUMETSAT.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250720937880/en/
CONTACT: Media Relations EUMETSAT:
Tel. : +49 6151 807 7320
Email:[email protected]
www.eumetsat.int
KEYWORD: GERMANY EUROPE
INDUSTRY KEYWORD: SATELLITE SCIENCE OTHER SCIENCE RESEARCH TECHNOLOGY
SOURCE: EUMETSAT
Copyright Business Wire 2025.
PUB: 07/21/2025 02:00 AM/DISC: 07/21/2025 02:01 AM
http://www.businesswire.com/news/home/20250720937880/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
4 minutes ago
- Fast Company
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022. The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision. But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid. Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal. Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal. 'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added. Moderna did not immediately respond to a request for comment. Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic. The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
Yahoo
3 hours ago
- Yahoo
H.C. Wainwright Reaffirms Buy on argenx (ARGX), Highlights Pipeline Progress
argenx SE (NASDAQ:ARGX) is one of the high growth stocks outside tech analysts are bullish on. H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating on argenx SE (NASDAQ:ARGX) as of July 1, citing strong progress in the company's neuromuscular treatment pipeline. With a current market price of $598.40 and Bank of America's price target of $804, the stock offers a potential upside of about 34.3%. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. The bullish stance is driven by the advancement of ARGX-119, now entering a registrational trial for congenital myasthenic syndromes (CMS). This marks the company's third molecule to reach late-stage clinical development. Positive Phase 1b results showed promising safety and consistent improvements in patient outcomes, which boosted investor confidence. ARGX-119 also highlights the growing potential of argenx's SIMPLE Antibody platform, a proprietary technology for developing precise antibody-based therapies. The ongoing natural history study in CMS is expected to add valuable, real-world insight that could support regulatory submissions. The company is also conducting a Phase 2a study of ARGX-119 in amyotrophic lateral sclerosis (ALS), a move that could broaden its future treatment offerings. If successful, ARGX-119 could become the first therapy approved for DOK7-CMS, a very rare form of neuromuscular disease. argenx develops antibody-based therapies for rare autoimmune and neuromuscular disorders. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
3 hours ago
- Yahoo
Compact detector unlocks reactor's neutrino mystery with first-ever detection
Scientists at the Max Planck Institute for Nuclear Physics (MPIK) have detected antineutrinos from a nuclear reactor using a 3 kg (6.6 lbs) detector. The results were achieved using the CONUS+ experiment and provide an observation of Coherent Elastic Neutrino-Nucleus Scattering (CEvNS) from a reactor source at full coherence. 'The CEvNS measurement provides unique insights into fundamental physical processes within the Standard Model of particle physics, the current theory describing the structure of our universe,' said the researchers in a press release. Neutrinos do not scatter off The experiment is situated 20.7 meters from the core of the Leibstadt nuclear power plant in Switzerland. It uses three 1 kg (2.2 lbs) germanium semiconductor detectors to identify CEvNS, a process where a low-energy neutrino interacts with an entire atomic nucleus. 'In this process, neutrinos do not scatter off the individual components of the atomic nuclei in the detector, but rather coherently with the entire nucleus. This significantly increases the probability of a very small but observable nuclear recoil,' explained the press release. The process can be compared to a ping-pong ball hitting a car; the recoil of the car, though small, is the observable effect. In this case, antineutrinos from the reactor scattered off germanium nuclei in the detectors. Over a measurement period of 119 days between 2023 and 2024, the team recorded an excess of 395±106 neutrino signals after subtracting background and interfering signals. The position of the detector receives a flux of more than 1013 (ten trillion) neutrinos per square centimeter per second from the reactor. "This value is in very good agreement with theoretical calculations, within the measurement uncertainty," remarked the press release. "We have thus successfully confirmed the sensitivity of the CONUS+ experiment and its ability to detect antineutrino scattering from atomic nuclei," added Dr. Christian Buck, an author of the study. Neutrino detection requires large experiments Neutrinos are elementary particles that interact weakly with matter, and their detection has typically required very large experiments. The CEvNS effect was theorized in 1974 and first observed by the COHERENT experiment at a particle accelerator in 2017. The CONUS+ result is the first observation of the effect from a reactor at these low energies. The CEvNS technique may have future applications. Dr. Buck noted the potential to develop small, mobile neutrino detectors to monitor reactor heat output or isotope concentration. The measurement also provides data for testing the Standard Model of particle physics. According to the authors, the CONUS+ measurements have a reduced dependence on nuclear physics aspects compared to other experiments, improving the sensitivity to physics beyond the Standard Model. "The techniques and methods used in CONUS+ have excellent potential for fundamental new discoveries," concluded Professor Manfred Lindner, the project's initiator. "The groundbreaking CONUS+ results could therefore mark the starting point for a new field in neutrino research." The experiment was equipped with improved and larger detectors in autumn 2024, with the aim of increasing measurement accuracy. Solve the daily Crossword
